ACM: Funding, Investors & Team (Sep 2026)
At ACM Biolabs, we are focused on developing novel vaccines and antibodies using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional, folded membrane proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and have a growing pipeline of vaccine and antibodies. The company is headquartered in Singapore, and has been operational since 2013.
ACM has raised $6.8M across 1 funding round on record, the most recent an undisclosed round of $6.8M announced in Sep 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ACM Company Profile and Key Stats
Latest funding round on record: Sep 2022.
ACM Funding Rounds
ACM Founders and Leadership Team
No contact details are on record for this team yet.
ACM Funding Compared to Other Biotechnology Startups
ACM's latest round of $6.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ACM in Biotechnology and Singapore
Companies Similar to ACM
YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting…
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based…
ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the…
Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic…
Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and…
Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare…
BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by…
Auristone delivers practical clinical insights through our epigenomics workflows, providing actionable…
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in…
GDMC is a pharmaceutical organization that specializes in the production and development of genetic…
Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat…
Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food…
ACM Funding FAQs
What does ACM do?
At ACM Biolabs, we are focused on developing novel vaccines and antibodies using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional, folded membrane proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and have a growing pipeline of vaccine and antibodies. The company is headquartered in Singapore, and has been operational since 2013.
How much funding has ACM raised?
ACM has raised $6.8M across 1 round on record. The most recent is an undisclosed round of $6.8M announced in Sep 2022.
When did ACM last raise funding?
ACM's most recent funding round on record is an undisclosed round of $6.8M, announced in Sep 2022.
Who is the CEO of ACM?
Madhavan Nallani is listed as CEO at ACM.
Where is ACM headquartered?
ACM is based in Singapore, Central Region, Singapore.
How many employees does ACM have?
ACM is in the 11-50 employee band.
How does ACM's funding compare to other Biotechnology startups?
ACM's latest round of $6.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's ACM Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ACM is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.